Literature DB >> 16598493

New drugs from marine microbes: the tide is turning.

David J Newman1, Russell T Hill.   

Abstract

This is a mini-review demonstrating that investigation of the genomics of marine microbes from all three domains has the potential to revolutionize the search for secondary metabolites originally thought to be the product of marine invertebrates. The basis for the review was a symposium at the 2005 Annual Meeting of the SIM covering some aspects of the potential for marine microbes to be the primary producers of such metabolites. The work reported at that symposium has been integrated into a fuller discussion of current published literature on the subject with examples drawn from bacteria, cyanophytes and fungi.

Mesh:

Substances:

Year:  2006        PMID: 16598493     DOI: 10.1007/s10295-006-0115-2

Source DB:  PubMed          Journal:  J Ind Microbiol Biotechnol        ISSN: 1367-5435            Impact factor:   3.346


  31 in total

1.  Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

Authors:  Robert H Feling; Greg O Buchanan; Tracy J Mincer; Christopher A Kauffman; Paul R Jensen; William Fenical
Journal:  Angew Chem Int Ed Engl       Date:  2003-01-20       Impact factor: 15.336

2.  Molecular evidence for a uniform microbial community in sponges from different oceans.

Authors:  Ute Hentschel; Jörn Hopke; Matthias Horn; Anja B Friedrich; Michael Wagner; Jörg Hacker; Bradley S Moore
Journal:  Appl Environ Microbiol       Date:  2002-09       Impact factor: 4.792

3.  Discovery of the novel candidate phylum "Poribacteria" in marine sponges.

Authors:  Lars Fieseler; Matthias Horn; Michael Wagner; Ute Hentschel
Journal:  Appl Environ Microbiol       Date:  2004-06       Impact factor: 4.792

4.  Microbial genomics as a guide to drug discovery and structural elucidation: ECO-02301, a novel antifungal agent, as an example.

Authors:  James B McAlpine; Brian O Bachmann; Mahmood Piraee; Steve Tremblay; Anne-Marie Alarco; Emmanuel Zazopoulos; Chris M Farnet
Journal:  J Nat Prod       Date:  2005-04       Impact factor: 4.050

5.  A molecular systematic survey of cultured microbial associates of deep-water marine invertebrates.

Authors:  Karen Sfanos; Dedra Harmody; Phat Dang; Angela Ledger; Shirley Pomponi; Peter McCarthy; Jose Lopez
Journal:  Syst Appl Microbiol       Date:  2005-04       Impact factor: 4.022

6.  From peptide precursors to oxazole and thiazole-containing peptide antibiotics: microcin B17 synthase.

Authors:  Y M Li; J C Milne; L L Madison; R Kolter; C T Walsh
Journal:  Science       Date:  1996-11-15       Impact factor: 47.728

7.  New cytotoxic salinosporamides from the marine Actinomycete Salinispora tropica.

Authors:  Philip G Williams; Greg O Buchanan; Robert H Feling; Christopher A Kauffman; Paul R Jensen; William Fenical
Journal:  J Org Chem       Date:  2005-08-05       Impact factor: 4.354

8.  Genomic mining for Aspergillus natural products.

Authors:  Jin Woo Bok; Dirk Hoffmeister; Lori A Maggio-Hall; Renato Murillo; Jeremy D Glasner; Nancy P Keller
Journal:  Chem Biol       Date:  2006-01

9.  Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.

Authors:  Venkat R Macherla; Scott S Mitchell; Rama Rao Manam; Katherine A Reed; Ta-Hsiang Chao; Benjamin Nicholson; Gordafaried Deyanat-Yazdi; Bao Mai; Paul R Jensen; William F Fenical; Saskia T C Neuteboom; Kin S Lam; Michael A Palladino; Barbara C M Potts
Journal:  J Med Chem       Date:  2005-06-02       Impact factor: 7.446

10.  Posttranslational modifications in microcin B17 define an additional class of DNA gyrase inhibitor.

Authors:  P Yorgey; J Lee; J Kördel; E Vivas; P Warner; D Jebaratnam; R Kolter
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

View more
  31 in total

1.  Comparison of the bacterial communities of wild and captive sponge Clathria prolifera from the Chesapeake Bay.

Authors:  LeLeng To Isaacs; Jinjun Kan; Linh Nguyen; Patrick Videau; Matthew A Anderson; Toby L Wright; Russell T Hill
Journal:  Mar Biotechnol (NY)       Date:  2009-05-15       Impact factor: 3.619

Review 2.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

3.  Isolation of high molecular weight DNA from marine sponge bacteria for BAC library construction.

Authors:  Yongchang Ouyang; Shikun Dai; Lianwu Xie; M S Ravi Kumar; Wei Sun; Huimin Sun; Danling Tang; Xiang Li
Journal:  Mar Biotechnol (NY)       Date:  2009-08-15       Impact factor: 3.619

4.  Nature's bounty - drug discovery from the sea.

Authors:  John J Bowling; Anna J Kochanowska; Noer Kasanah; Mark T Hamann
Journal:  Expert Opin Drug Discov       Date:  2007-11       Impact factor: 6.098

Review 5.  Natural products: a continuing source of novel drug leads.

Authors:  Gordon M Cragg; David J Newman
Journal:  Biochim Biophys Acta       Date:  2013-02-18

6.  Biogeography and host fidelity of bacterial communities in Ircinia spp. from the Bahamas.

Authors:  Lucía Pita; Susanna López-Legentil; Patrick M Erwin
Journal:  Microb Ecol       Date:  2013-03-26       Impact factor: 4.552

Review 7.  Marine drugs from sponge-microbe association--a review.

Authors:  Tresa Remya A Thomas; Devanand P Kavlekar; Ponnapakkam A LokaBharathi
Journal:  Mar Drugs       Date:  2010-04-22       Impact factor: 5.118

Review 8.  Marine antitumor drugs: status, shortfalls and strategies.

Authors:  Ira Bhatnagar; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2010-10-15       Impact factor: 5.118

Review 9.  Immense essence of excellence: marine microbial bioactive compounds.

Authors:  Ira Bhatnagar; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2010-10-15       Impact factor: 5.118

Review 10.  Towards commercial production of sponge medicines.

Authors:  Marieke Koopmans; Dirk Martens; Rene H Wijffels
Journal:  Mar Drugs       Date:  2009-12-02       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.